Cover Image
市場調查報告書

癌症的免疫治療市場分析:各產品(單株抗體,免疫調節藥物,腫瘤溶解性病毒治療,癌症疫苗),癌症類別,及市場區隔預測

Cancer Immunotherapy Market Analysis By Product (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies, Cancer Vaccines), By Cancer Type, And Segment Forecasts, 2014 - 2025

出版商 Grand View Research, Inc. 商品編碼 581988
出版日期 內容資訊 英文 75 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
癌症的免疫治療市場分析:各產品(單株抗體,免疫調節藥物,腫瘤溶解性病毒治療,癌症疫苗),癌症類別,及市場區隔預測 Cancer Immunotherapy Market Analysis By Product (Monoclonal Antibodies, Immunomodulators, Oncolytic Viral Therapies, Cancer Vaccines), By Cancer Type, And Segment Forecasts, 2014 - 2025
出版日期: 2017年10月05日 內容資訊: 英文 75 Pages
簡介

本報告提供全球癌症的免疫治療市場相關調查,彙整市場概要和各各產品,癌症類別,及各地區的趨勢,加入此市場的主要企業簡介等資料。

第1章 調查方法

第2章 摘要整理

第3章 市場變動,趨勢,範圍

  • 市場區隔和範圍
  • 推動市場的要素分析
  • 阻礙市場的要素分析
  • SWOT分析
  • 產業分析:波特五力分析
  • 開發平台分析

第4章 各產品預測與趨勢分析

  • 趨勢分析
  • 單株抗體
  • 免疫調節藥物
  • 腫瘤溶解性病毒治療及癌症疫苗

第5章 癌症類別預測與趨勢分析

  • 趨勢分析
  • 肺癌
  • 乳癌
  • 大腸癌
  • 黑色素瘤
  • 前列腺癌
  • 頭頸癌
  • 卵巢癌

第6章 各地區預測與趨勢分析

  • 趨勢分析
  • 北美
  • 歐洲
  • 亞太地區
  • 南美
  • 中東·非洲

第7章 競爭環境

  • 策略架構
  • 企業簡介
目錄
Product Code: GVR-1-68038-693-6

The global cancer immunotherapy market is expected to reach USD 118.8 billion by 2025, according to a new report by Grand View Research, Inc. Increasing patient pool and higher mortality rate are boosting the need for cancer immunotherapy globally. However, lack of awareness and adverse effects associated with immune therapeutic drugs are restraining market growth.

Cancer immunotherapy has been emerging as a new avenue for revenue generation for pharmaceutical companies. In addition, adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting demand for immunotherapy. Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is expected to initiate introduction of advanced therapeutics in the market.

Furthermore, increase in number of approvals for new immunotherapeutic drugs is driving the global market. Introduction of new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their ability to provide better cancer treatment.

Monoclonal antibodies are the most widely used immunotherapeutic drugs globally. Development of monoclonal antibodies as effective immunotherapeutic options started after the approval of Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell lymphoblastic leukemia. Increasing investments in R&D pertaining to use of monoclonal bodies as naked antigen binding antibodies, conjugated monoclonal antibodies, and bispecific antibodies have resulted in discovery of new therapeutic options for cancer treatment. Technological advancements, such as radiation and nanoparticle therapies, are boosting the cancer immunotherapy market. Majority of cancer immunotherapy drugs have been used in treatment of non-small cell lung cancer, breast cancer, and prostate cancer.

Further Key Findings from the Report Suggest:

Monoclonal antibodies emerged as the largest segment because of increasing regulatory approvals and higher efficacy

Lung cancer accounted for the largest share in the cancer type segment owing to rise in demand for immunotherapeutic drugs in its treatment

North America dominated the market with the largest share in 2016. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period

Europe is projected to witness rapid growth during the forecast period owing to rapid adoption of advanced cancer therapeutics for effective cancer treatment

Some of the key players are Amgen, Inc.; AstraZeneca; F. Hoffmann La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck and Co., Inc.; Novartis AG; and Pfizer, Inc. dominated the global cancer immunotherapy market.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Information procurement
  • 1.2 Data Analysis
  • 1.3 Approaches for market estimation
    • 1.3.1 Approach 1: Demand Analysis & Bottom up Approach
    • 1.3.2 Approach 2: Top down market estimation
    • 1.3.3 Approach 3: Commodity flow and bottom up market estimation
    • 1.3.4 Approach 4: KoL perspective based market sizing

Chapter 2 Executive Summary

  • 2.1 Market Snapshot

Chapter 3 Cancer Immunitherapy Market Variables, Trends & Scope

  • 3.1 Market segmentation & scope
  • 3.2 Market Driver Analysis
  • 3.3 Market Restraint Analysis
  • 3.4 Cancer Immunotherapy Market - SWOT Analysis, By Factor (political & legal, economic and technological)
  • 3.5 Industry Analysis - Porter's
    • 3.5.1 Threat of new entrants
    • 3.5.2 Competitive Rivalry
    • 3.5.3 Bargaining power of suppliers
    • 3.5.4 Bargaining power of buyers
    • 3.5.5 Threat of substitutes
  • 3.6 Pipeline Analysis, By Key Company, 2016

Chapter 4 Cancer Immunotherapy Market: Product Estimates & Trend Analysis

  • 4.1 Cancer Immunotherapy Market: Product movement analysis
  • 4.2 Monoclonal Antibodies
    • 4.2.1 Market Estimates and Forecast, 2014 - 2024 (USD Billion)
  • 4.3 Immunomodulators
    • 4.3.1 Market Estimates and Forecast, 2014 - 2024 (USD Billion)
  • 4.4 Oncolytic viral therapies and cancer vaccines
    • 4.4.1 Market Estimates and Forecast, 2014 - 2024 (USD Billion)

Chapter 5 Cancer Immunotherapy Market : Cancer Type Estimates and Trend Analysis

  • 5.1 Cancer immunotherapy market: Application movement analysis
  • 5.2 Lung cancer
    • 5.2.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 5.3 Breast cancer
    • 5.3.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 5.4 Colorectal cancer
    • 5.4.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 5.5 Melanoma
    • 5.5.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 5.6 Prostate cancer
    • 5.6.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 5.7 Head and neck cancer
    • 5.7.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)
  • 5.8 Ovarian cancer
    • 5.8.1 Market Estimates and Forecast, 2014 - 2025 (USD Billion)

Chapter 6 Regional Estimates & Trend Analysis, by Product and Cancer Type

  • 6.1 Cancer Immunotherapy Market: Regional movement analysis
  • 6.2 North America
    • 6.2.1 U.S.
      • 6.2.1.1 Market Estimates and Forecast, by Product, 2014 - 2025 (USD Billion)
      • 6.2.1.2 Market Estimates and Forecast, by Cancer Type, 2014 - 2025 (USD Billion)
    • 6.2.2 Canada
      • 6.2.2.1 Market Estimates and Forecast, by Product, 2014 - 2025 (USD Billion)
      • 6.2.2.2 Market Estimates and Forecast, by Cancer Type, 2014 - 2025 (USD Billion)
  • 6.3 Europe
    • 6.3.1 U.K.
      • 6.2.1.1 Market Estimates and Forecast, by Product, 2014 - 2025 (USD Billion)
      • 6.3.1.2 Market Estimates and Forecast, by Cancer Type, 2014 - 2025 (USD Billion)
    • 6.3.2 Germany
      • 6.2.2.1 Market Estimates and Forecast, by Product, 2014 - 2025 (USD Billion)
      • 6.3.2.2 Market Estimates and Forecast, by Cancer Type, 2014 - 2025 (USD Billion)
  • 6.4 Asia Pacific
    • 6.4.1 China
      • 6.4.1.1 Market Estimates and Forecast, by Product, 2014 - 2025 (USD Billion)
      • 6.4.1.2 Market Estimates and Forecast, by Cancer Type, 2014 - 2025 (USD Billion)
    • 6.4.2 Japan
      • 6.4.2.1 Market Estimates and Forecast, by Product, 2014 - 2025 (USD Billion)
      • 6.4.2.2 Market Estimates and Forecast, by Cancer Type, 2014 - 2025 (USD Billion)
  • 6.5 Latin America
    • 6.5.1 Brazil
      • 6.5.1.1 Market Estimates and Forecast, by Product, 2014 - 2025 (USD Billion)
      • 6.5.1.2 Market Estimates and Forecast, by Cancer Type, 2014 - 2025 (USD Billion)
    • 6.5.2 Mexico
      • 6.5.1.1 Market Estimates and Forecast, by Product, 2014 - 2025 (USD Billion)
      • 6.5.1.2 Market Estimates and Forecast, by Cancer Type, 2014 - 2025 (USD Billion)
  • 6.6 Middle East and Africa (MEA)
    • 6.6.1 South Africa
      • 6.6.1.1 Market Estimates and Forecast, by Product, 2014 - 2025 (USD Billion)
      • 6.6.1.2 Market Estimates and Forecast, by Cancer Type, 2014 - 2025 (USD Billion)

Chapter 7 Competitive Landscape

  • 7.1 Strategy framework
  • 7.2 Company Profiles
  • 7.3 AstraZeneca
    • 7.3.1 Company Overview
    • 7.3.2 Financial Performance
    • 7.3.3 Geographic Footprint
    • 7.3.4 Product Benchmarking
    • 7.3.5 Strategic Initiatives
  • 7.4 Amgen, Inc.
    • 7.4.1 Company Overview
    • 7.4.2 Financial Performance
    • 7.4.3 Geographic Footprint
    • 7.4.4 Product Benchmarking
    • 7.4.5 Strategic Initiatives
  • 7.5 F. Hoffman-La Roche Ltd.
    • 7.5.1 Company Overview
    • 7.5.2 Financial Performance
    • 7.5.3 Geographic Footprint
    • 7.5.4 Product Benchmarking
    • 7.5.5 Strategic Initiatives
  • 7.6 Bristol-Myers Squibb Company
    • 7.6.1 Company Overview
    • 7.6.2 Financial Performance
    • 7.6.3 Geographic Footprint
    • 7.6.4 Product Benchmarking
    • 7.6.5 Strategic Initiatives
  • 7.7 Novartis AG
    • 7.7.1 Company Overview
    • 7.7.2 Financial Performance
    • 7.7.3 Geographic Footprint
    • 7.7.4 Product Benchmarking
    • 7.7.5 Strategic Initiatives
  • 7.8 Merck & Co., Inc.
    • 7.8.1 Company Overview
    • 7.8.2 Financial Performance
    • 7.8.3 Geographic Footprint
    • 7.8.4 Product Benchmarking
  • 7.8 5 Strategic Initiatives
  • 7.9 Pfizer Inc.
    • 7.9.1 Company Overview
    • 7.9.2 Financial Performance
    • 7.9.3 Geographic Footprint
    • 7.9.4 Product Benchmarking
    • 7.9.5 Strategic Initiatives

List of Tables

  • TABLE 1 North America Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 2 North America Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 3 U.S. Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 4 U.S. Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 5 Canada Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 6 Canada Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 7 Europe Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 8 Europe Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 9 U.K. Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 10 U.K. Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 11 Germany Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 12 Germany Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 13 Asia Pacific Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 14 Asia Pacific Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 15 Japan Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 16 Japan Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 17 China Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 18 China Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 19 Latin America Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 20 Latin America Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 21 Brazil Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 22 Brazil Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 23 Mexico Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 24 Mexico Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 25 MEA Cancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 26 MEA Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)
  • TABLE 27 South AfircaCancer immunotherapy market, by product, 2014 - 2025 (USD Billion)
  • TABLE 28 South Africa Cancer immunotherapy market, by cancre type, 2014 - 2025 (USD Billion)

List of Figures

  • FIG. 1 Market research process
  • FIG. 2 Information procurement
  • FIG. 3 Primary research pattern
  • FIG. 4 Market research approaches
  • FIG. 5 Value chain based sizing & forecasting
  • FIG. 6 QFD modelling for market share assessment
  • FIG. 7 Market summary (USD Million)
  • FIG. 8 Market trends & outlook
  • FIG. 9 Market segmentation & scope
  • FIG. 10 Market driver relevance analysis (Current & future impact)
  • FIG. 11 Market restraint relevance analysis (Current & future impact)
  • FIG. 12 SWOT Analysis, By Factor (political & legal, economic and technological)
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 Cancer Immunotherapy Market: Product movement analysis
  • FIG. 15 Monoclonal antibodies market, 2014 - 2025 (USD Million)
  • FIG. 16 Immunomodulators market, 2014 - 2025 (USD Million)
  • FIG. 17 Oncolytic viral therapies and cancer vaccines market, 2014 - 2025 (USD Million)
  • FIG. 18 Cancer Immunotherapy Market: Application movement analysis
  • FIG. 19 Lung cancer market, 2014- 2025 (USD Million)
  • FIG. 20 Breast cancer market, 2014 - 2025 (USD Million)
  • FIG. 21 Colorectal cancer market, 2014 - 2025 (USD Million)
  • FIG. 22 Melanoma market, 2014 - 2025 (USD Million)
  • FIG. 23 Prostate cancer market, 2014- 2025 (USD Million)
  • FIG. 24 Head and Neck cancer market, 2014 - 2025 (USD Million)
  • FIG. 25 Ovarian cancer market, 2014 - 2025 (USD Million)
  • FIG. 26 Regional market place: Key takeaways
  • FIG. 27 Cancer Immunotherapy Market: regional movement analysis
  • FIG. 28 Germany cancer prevalence, incidence and mortality rate:
  • FIG. 29 Strategy framework
Back to Top